Explore

US Government Launches $144M Initiative to Combat Microplastics in Human Body

US Government Launches $144M Initiative to Combat Microplastics in Human Body

The United States Department of Health and Human Services (HHS) has announced a $144 million initiative to address the issue of microplastics in the human body. The program, named Systematic Targeting Of MicroPlastics (STOMP), aims to measure microplastics and nanoplastics in human bodies and research their effects. HHS Secretary Robert F. Kennedy, Jr. emphasized the need for clear answers regarding the health impacts of microplastics. The initiative will focus on developing tools to measure microplastic exposure, identify sources of risk, and create solutions to reduce their presence in the body. The program will be led by ARPA-H and aims to establish standardized measurement methods and interventions to address microplastic-related health concerns.

Irregular Sleep Patterns Linked to Increased Cardiovascular Risk

Irregular Sleep Patterns Linked to Increased Cardiovascular Risk

A study involving over 3,000 middle-aged adults has found that consistent bedtimes are associated with a lower risk of major cardiovascular problems, such as heart attack and stroke. Conducted over nearly a decade, the research used wearable devices to track participants' sleep patterns. It revealed that irregular bedtimes and variable mid-sleep times significantly increase the risk of cardiac events. Conversely, getting more than eight hours of sleep per night appeared to mitigate heart issues. The study suggests that regular bedtimes may be crucial for heart health as they align with the body's circadian rhythms, which govern vital processes. Additionally, a separate study highlighted that fluctuating sleep apnea severity could impose strain on the heart, linking severe apnea and habitual snoring to faster vascular aging.

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

A study published in Nature by 23andMe has identified genetic variants that explain the varied responses to obesity drugs like semaglutide and tirzepatide. The research involved nearly 28,000 participants who used 23andMe's DNA-testing service and reported their experiences with weight-loss drugs. The study found that specific genetic variants are associated with greater weight loss and increased risk of side effects such as nausea. These findings provide insights into why some individuals experience significant weight loss while others do not, highlighting the role of genetics in drug efficacy and side effects.

HHS Launches $144M Initiative to Address Microplastics in Human Health

HHS Launches $144M Initiative to Address Microplastics in Human Health

The U.S. Department of Health and Human Services (HHS) has announced a $144 million initiative to investigate the impact of microplastics on human health. The program, named Systematic Targeting Of MicroPlastics (STOMP), is spearheaded by the Advanced Research Projects Agency for Health (ARPA-H). The initiative aims to measure microplastic exposure in humans, identify sources of risk, and develop solutions to mitigate these risks. Microplastics, which are nearly invisible, have been found in human lungs, arterial plaques, and brains, raising concerns about their potential to cause disease. The program will focus on developing affordable and accessible tools to measure and understand the distribution and effects of microplastics in the body.

NIH Researchers Develop New Opioid with Reduced Addiction Risk

NIH Researchers Develop New Opioid with Reduced Addiction Risk

Researchers at the National Institutes of Health (NIH) have developed a new opioid compound that offers strong pain relief without the typical risks of addiction and respiratory depression. This new compound, derived from a class of synthetic opioids known as nitazenes, was tested in laboratory animals and showed promising results. The study, published in Nature, highlights the compound's ability to provide effective pain relief while minimizing adverse effects commonly associated with opioids. The research team focused on modifying the nitazenes to retain their pain-relieving properties while reducing their potency to improve safety. The compound, referred to as DFNZ, demonstrated a safer pharmacological profile, avoiding respiratory depression and showing minimal withdrawal symptoms in preclinical tests.

Irregular Sleep Patterns Linked to Increased Heart Attack and Stroke Risk

Irregular Sleep Patterns Linked to Increased Heart Attack and Stroke Risk

A study from the University of Oulu in Finland, published in BMC Cardiovascular Disorders, finds that irregular sleep patterns and sleeping less than eight hours per night significantly increase the risk of major adverse cardiovascular events (MACE), such as heart attacks and strokes. The research involved over 3,000 adults and highlighted the importance of maintaining a regular sleep schedule for heart health. The study aligns with CDC recommendations for adults to get at least seven hours of sleep per night, noting that a third of U.S. adults fail to meet this guideline.

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

Research Highlights Potential of Wildflower Tormentil in Combating Antibiotic-Resistant Superbugs

Research Highlights Potential of Wildflower Tormentil in Combating Antibiotic-Resistant Superbugs

Recent research has revealed that the wildflower tormentil, traditionally used in Irish and European medicine, shows promise in fighting antibiotic-resistant superbugs. The study focused on the antimicrobial properties of tormentil, a small yellow wildflower, which was historically used to treat wounds, sore throats, and other infections. Researchers tested extracts from over 70 plant species, including tormentil, against bacteria that cause severe infections. The results indicated that tormentil extracts not only inhibited bacterial growth but also prevented the formation of biofilms, which protect bacteria from antibiotics. The study also found that tormentil extracts could enhance the efficacy of existing antibiotics, such as colistin, when used in combination. This discovery is significant as antimicrobial resistance poses a growing global threat, making some infections difficult or impossible to treat.

23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

A study conducted by the research arm of genetic testing company 23andMe has identified genetic variations that influence the effectiveness and side effects of GLP-1 agonist-based weight-loss drugs. The study analyzed the genomes of nearly 28,000 users of these drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Researchers found a missense variant in the GLP1R gene associated with greater weight loss and multiple variants in the GIPR gene linked to increased susceptibility to side effects like nausea and vomiting. These findings, published in the journal Nature, suggest that genetic testing could help tailor weight-loss treatments to individual patients, enhancing efficacy and safety.

Silicosis Cases from Countertop Silica Dust Lead to Rising Litigation

Silicosis Cases from Countertop Silica Dust Lead to Rising Litigation

Silicosis, a progressive occupational lung disease caused by inhaling crystalline silica dust, is leading to increasing litigation in the U.S. Tyler Jordan, a former countertop fabricator diagnosed with silicosis, is suing manufacturers of engineered stone, including Cambria Co. LLC and Caesarstone USA Inc. His case is set to go to trial in Denver, following a landmark jury verdict in California that awarded $52 million to a former fabricator. An estimated 100,000 U.S. workers in the stone fabrication industry have been exposed to high levels of silica dust, prompting concerns about a potential wave of lawsuits similar to those seen with black lung and asbestos-related diseases.

Epic Systems Launches Health Alerts Tracker to Monitor Elevated Illness Rates

Epic Systems Launches Health Alerts Tracker to Monitor Elevated Illness Rates

Epic Systems has introduced a new monitoring system called Health Alerts, designed to track and flag areas with elevated illness rates across the United States. This system utilizes data from Epic's Cosmos database to send notifications when there is a higher-than-usual number of disease diagnoses in specific counties. The initiative aims to provide timely alerts to healthcare providers and public health officials, enabling them to respond more effectively to emerging health trends and potential outbreaks.

American Heart Association Issues Dietary Guidance Diverging from U.S. Dietary Guidelines

American Heart Association Issues Dietary Guidance Diverging from U.S. Dietary Guidelines

The American Heart Association (AHA) has released its 2026 Dietary Guidance to Improve Cardiovascular Health, which presents recommendations that differ from the 2025-2030 U.S. Dietary Guidelines for Americans (DGA). The AHA advises a shift from meat to plant-based protein sources, such as legumes, nuts, and seeds, while also recommending regular consumption of fish and seafood. The guidance suggests limiting red meat intake to lean cuts and avoiding processed meats to reduce saturated fat and sodium consumption. The AHA's stance on dairy also contrasts with the DGA, as it continues to recommend low-fat or fat-free dairy products over full-fat options. Additionally, the AHA emphasizes the consumption of whole grains over refined grains, aligning with the DGA's preference for whole grains but differing in its approach to refined grains.